AI assistant
ArcticZymes Technologies — M&A Activity 2023
May 3, 2023
3538_rns_2023-05-03_0851bc7d-80d6-4596-a6c5-3720ba42930b.pdf
M&A Activity
Open in viewerOpens in your device viewer
ArcticZymes Technologies and Genovis enter into a collaboration agreement to accelerate growth in China.
Tromsø, May 3rd 2023 – ArcticZymes Technologies ASA (OSE: AZT) and Genovis are excited to announce a collaboration to speed up penetration and growth in the Chinese market.
The collaboration will create several synergies that will allow both companies to tap into the projected growth potential in China for their respective market segments. The focus of the collaboration will be on sharing Business Development resources and engaging in joint Marketing activities. The joint effort will allow both companies to have a direct presence in the Chinese market with local resources.
According to Dirk Hahneiser, VP of Business Development & Marketing, ArcticZymes: "Sharing our resources will not only leverage economies of scale, increased profitability, and long-term value creation for shareholders, but also frees up resources to focus even more on our customers and their needs."
Rikke Rytter, VP Sales & Marketing at Genovis, says, "We're excited about the collaboration because joining forces enables both Nordic enzyme companies to leverage synergies, amplify impact, mitigate risk, and expand our respective presence in this fast-growing market."
For more information, please contact:
ArcticZymes Technologies ASA
CFO, Børge Sørvoll Tel: +47 952 90187
Genovis AB
CEO, Fredrik Olsson Tel: +46 (0)70 276 46 56 [email protected]
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
The company is listed on the Oslo Stock Exchange since 2005 as ArcticZymes Technologies under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA
Innovation Centre. ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents.
For more information, please visit the website: www.arcticzymes.com.
About Genovis AB
Genovis' business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company's Certified Adviser, [email protected], tel: +46 (0)8-463 83 00.